Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis - Top-Institutions - MDSpire

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • By

  • Jeffrey Crowley

  • Eingun James Song

  • Linda Stein-Gold

  • Paolo Gisondi

  • Christopher G. Bunick

  • Vishvas Garg

  • Emanuele Leoncini

  • Blair Kaplan

  • Richard Ta

  • Bang Truong

  • Dolly Sharma

  • Bruce Strober

  • July 2, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Dermatology

  • #2

    University of Pennsylvania, Perelman School of Medicine
    University of Pennsylvania, Perelman School of Medicine

    Philadelphia, Pennsylvania

    Key Differentiators

    • Dermatology

  • #3

    CorEvitas Psoriasis Registry
    CorEvitas Psoriasis Registry

    Not specified, Not specified

    Key Differentiators

    • Dermatology

  • #4

    National Institute for Health and Care Excellence Support Unit
    National Institute for Health and Care Excellence Support Unit

    Not specified, Not specified

    Key Differentiators

    • Dermatology

  • #5

    Huashan Hospital, Fudan University
    Huashan Hospital, Fudan University

    Shanghai, China

    Key Differentiators

    • Dermatology

Original Source(s)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

  • July 2, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

Skin barrier dysfunction and correlation with the onset and progression of psoriasis